Contributions
Abstract: EP1493
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 15 Immunology
Background: Most patients with NMO/ NMOSD have autoantibodies against aquaporin-4 (AQP4-Ab), but recently, myelin-oligodendrocyte glycoprotein antibodies (MOG-Abs) have been found in some patients with childhood and adult demiyelinating diseases.
Aim: To evaluate the clinical features of patients with NMO/NMOSD with MOG-Ab and to compare them with patients with AQP4-Ab-positive NMO/NMOSD, and multiple sclerosis.
Methods: This observational study was conducted at Dokuz Eylul Üniversity Hospital in specialist center for demiyelinating disease. We examined AQP4 antibody and MOG antibody in 62 NMO/NMOSD and 33 Multiple sclerosis (MS) patients with ON. Groups were statistically matched age, gender, onset age, disease duration and disease severity. The diagnosis of NMO/NMOSD was made according to Wingerchuck criteria (2006). Cell-based assays were used to test patient serum samples for AQP4-Abs and MOG-Abs.
Results: None of thirty-three MS patients with ON had AQP4-Ab and MOG antibody. Five patients with atipic agressive demiyelinating disease had both antibodies. In one of 3 ADEM patients with LETM, MOG-Ab was positive (all AQP4-Ab negative). In only one of 17 LETM patients, MOG-Ab was positive and all of them was NMO-IgG negative. MOG antibody was not detected in any of 23 NMO patients with AQP4-Ab. In 2 of 10 relapsing ON patients MOG antibody and in 1 of the remainig patients AQP4-Ab was positive. These patients presented with simultaneous/sequential severe ON. Only one of 4 patients with area postrema syndrome had AQP4-Ab and none of them had MOG-Ab. Cerebrospinal fluid characteristics were different in the MS and NMO/NMOSD groups. OCBs were determined in 83% of MS patients and none of NMO/NMOSD had OCBs.
Conclusion: Only 4.8% of all patients in NMOSD group and 6.6% of patients in AQP4-Ab negative group had MOG-Ab. A higher proportion of AQP4-Ab-positive patients relapsed than MOG-Ab positive group despite similar follow-up durations but onset episode severity and outcomes from the onset episode did not differ between the 2 groups. MS had neither AQP4- Ab nor MOG-Ab.
Disclosure:
Egemen İdiman had no conflict of interest.
Fethi İdiman had no conflict of interest.
Mahmut Kaya had no conflict of İnterest.
Derya Kaya had no conflict of interest.
Omercan Hasankoyoglu had no conflict of interest.
Hatice Limoncu had no conflict of interest.
Onur Bulut had no conflict of interest.
Zekiye Altun had no conflictof interest.
Abstract: EP1493
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 15 Immunology
Background: Most patients with NMO/ NMOSD have autoantibodies against aquaporin-4 (AQP4-Ab), but recently, myelin-oligodendrocyte glycoprotein antibodies (MOG-Abs) have been found in some patients with childhood and adult demiyelinating diseases.
Aim: To evaluate the clinical features of patients with NMO/NMOSD with MOG-Ab and to compare them with patients with AQP4-Ab-positive NMO/NMOSD, and multiple sclerosis.
Methods: This observational study was conducted at Dokuz Eylul Üniversity Hospital in specialist center for demiyelinating disease. We examined AQP4 antibody and MOG antibody in 62 NMO/NMOSD and 33 Multiple sclerosis (MS) patients with ON. Groups were statistically matched age, gender, onset age, disease duration and disease severity. The diagnosis of NMO/NMOSD was made according to Wingerchuck criteria (2006). Cell-based assays were used to test patient serum samples for AQP4-Abs and MOG-Abs.
Results: None of thirty-three MS patients with ON had AQP4-Ab and MOG antibody. Five patients with atipic agressive demiyelinating disease had both antibodies. In one of 3 ADEM patients with LETM, MOG-Ab was positive (all AQP4-Ab negative). In only one of 17 LETM patients, MOG-Ab was positive and all of them was NMO-IgG negative. MOG antibody was not detected in any of 23 NMO patients with AQP4-Ab. In 2 of 10 relapsing ON patients MOG antibody and in 1 of the remainig patients AQP4-Ab was positive. These patients presented with simultaneous/sequential severe ON. Only one of 4 patients with area postrema syndrome had AQP4-Ab and none of them had MOG-Ab. Cerebrospinal fluid characteristics were different in the MS and NMO/NMOSD groups. OCBs were determined in 83% of MS patients and none of NMO/NMOSD had OCBs.
Conclusion: Only 4.8% of all patients in NMOSD group and 6.6% of patients in AQP4-Ab negative group had MOG-Ab. A higher proportion of AQP4-Ab-positive patients relapsed than MOG-Ab positive group despite similar follow-up durations but onset episode severity and outcomes from the onset episode did not differ between the 2 groups. MS had neither AQP4- Ab nor MOG-Ab.
Disclosure:
Egemen İdiman had no conflict of interest.
Fethi İdiman had no conflict of interest.
Mahmut Kaya had no conflict of İnterest.
Derya Kaya had no conflict of interest.
Omercan Hasankoyoglu had no conflict of interest.
Hatice Limoncu had no conflict of interest.
Onur Bulut had no conflict of interest.
Zekiye Altun had no conflictof interest.